Page 40 - 2019_06-Haematologica-web

W. Ghanima et al.
tomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012;87(5): 558-561.
31. Saleh MN, Bussel JB, Khelif A, et al. Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long- Term, Open-Label Extend Study. Blood. 2016;128(22):3742.
32. Steurer M, Quittet P, Papadaki HA, et al. A large observational study of patients with primary immune thrombocytopenia receiv- ing romiplostim in European clinical prac- tice. Eur J Haematol. 2017;98(2):112-120.
33. Grainger JD, Locatelli F, Chotsam- pancharoen T, et al. Eltrombopag for chil- dren with chronic immune thrombocytope- nia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386 (10004):1649-1658.
34. Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of chil- dren with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315-325.
35. Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45-54.
36. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical prac- tice: 2-year results of 72 adults in a romi- plostim compassionate-use program. Blood. 2011;118(16):4338-4345.
37. Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881-887.
38. Cantoni S, Carpenedo M, Mazzucconi MG, et al. Alternate use of thrombopoietin recep- tor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematol- ogy centers. Am J Hematol. 2018;93(1):58- 64.
39. Kuter DJ, Macahilig C, Grotzinger KM, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocy- topenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015;101(3): 255-263.
40. Mahevas M, Fain O, Ebbo M, et al. The tem- porary use of thrombopoietin-receptor ago- nists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165(6):865-869.
41. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romi- plostim in primary immune thrombocy- topenia: final results from a phase 2 study. Br J Haematol. 2016;172(2):262-273.
42. Gonzalez-Lopez TJ, Pascual C, Alvarez- Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocy- topenia. Am J Hematol. 2015;90(3):E40-43.
43. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombo- cytopenia associated with the use of throm- bopoietin receptor agonists. Transfusion. 2013;53(11):2807-2812.
44. Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and
patients with chronic idiopathic thrombocy- topenic purpura. J Clin Pharmacol. 2011;51(6):842-856.
45. Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, et al. Use of eltrombopag for sec- ondary immune thrombocytopenia in clini- cal practice. Br J Haematol. 2017;178(6):959- 970.
46. Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocy- topaenia (ITP) treated with the thrombopoi- etin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3):259-270.
47. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114(18): 3748-3756.
48. Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up. Haematologica. 2014;99(5):937-944.
49. Brynes RK, Wong RS, Thein MM, et al. A 2- Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. Acta Haematol. 2017;137(2):66-72.
50. Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treat- ment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016;95(7):1077-1087.
51. Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocy- topenia treated with eltrombopag: Data from the EXTEND study. Am J Hematol. 2015;90(7):598-601.
52. Imbach P, Crowther M. Thrombopoietin- receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365 (8):734-741.
53. Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romi- plostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91(5): 423-436.
54. Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodys- plastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5(1):e34-e43.
55. Fenaux P, Muus P, Kantarjian H, et al. Romiplostim monotherapy in thrombocy- topenic patients with myelodysplastic syn- dromes: long-term safety and efficacy. Br J Haematol. 2017;178(6):906-913.
patients with primary chronic immune thrombocytopenia: a Danish population- based cohort study. Br J Haematol. 2011;152(3):360-362.
59. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocy- topenia in the United Kingdom General Practice Research Database. Haematologica. 2010;95(7):1167-1175.
60. Norgaard M, Severinsen MT, Lund Maegbaek M, Jensen AO, Cha S, Sorensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocy- topenia: a Danish population-based cohort study. Br J Haematol. 2012;159(1):109-111.
61. Norgaard M, Cetin K, Maegbaek ML, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with pri- mary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174(4):639-642.
62. Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT. Comorbidities in patients with persistent or chronic immune thrombocy- topenia. Int J Hematol. 2010;92(2):289-295.
63. Rodeghiero F. Is ITP a thrombophilic disor- der? Am J Hematol. 2016;91(1):39-45.
64. Ramaswamy K, Hsieh L, Leven E, Thompson MV, Nugent D, Bussel JB. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocy- topenia in children. J Pediatr. 2014;165(3): 600-6055.e4.
65. Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo con- trolled study. Ann Hematol. 2011;90(11): 1341-1344.
66. Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocy- topenia. Haematologica. 2017;102(8):1342- 1351.
67. Rodeghiero F. ITP and thrombosis: an intriguing association. Blood Adv. 2017;1(24):2280.
68. Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119(17): 4066-4072.
69. Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost. 2013;109(4):676-683.
70. Garabet L, Ghanima W, Monceyron Jonassen C, et al. Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets. 2017:1-7.
71. Alvarez Roman MT, Fernandez Bello I, Arias-Salgado EG, et al. Effects of throm- bopoietin receptor agonists on procoagulant state in patients with immune thrombocy- topenia. Thromb Haemost. 2014;112(1):65-
56. Platzbecker U, Wong RS, Verma A, et al.
Safety and tolerability of eltrombopag ver-
sus placebo for treatment of thrombocy- 72.
topenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, ran- domised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015;2(10):e417-426.
57. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017;376(16):1540-1550.
58. Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in
72. Justo Sanz R, Monzon Manzano E, Fernandez Bello I, et al. Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. Thromb Haemost. 2019 Feb 11. [Epub ahead of print]
73. Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol. 2013;160(4):538-546.
1122
haematologica | 2019; 104(6)